medigraphic.com
ISSN 0016-3813 (Print)

2002, Number 1

<< Back Next >>

Gac Med Mex 2002; 138 (1)

The Controversy Between Estrogen Replacement Therapy and the Risk of Cancer of the Breast in Menopause.

Zárate A

Language: Spanish
References: 13
Page: 105-107
PDF size: 38.57 Kb.


ABSTRACT

At present, no information is available from controlled prospective randomized clinical trials to demonstrate a causal link between estrogen replacement therapy (HRT) and the risk of developing breast cancer. In most epidemiologic studies, HRT is not associated with an major increased risk of breast cancer; thus for women who had used estrogen for 10 years or more, the relative risk of breast cancer is 1.46 which is considered as small magnitude. Clinicians and patients are challenged with the difficult task of balancing the beneficial effects of HRT on cardiovascular and bone disease with the potential adverse effects on the breast. The analyses of the benefits and risks of HRT generally indicate that the benefits of therapy outweigh the risks. In other respect the number of survivors of breast cancer are increasing rapidly because of both early detection and the availability of more effective treatments. This effect will increase the number of hypoestrogenic survivors of breast cancer, a group that might benefit from HRT. However, the decision of using HRT has to be determined between the patient and the physician.


REFERENCES

  1. Harris JR, Lippman ME, Veronesi U, Willet W. Breast cancer. New Eng J Med 1993;327:319-28.

  2. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on screening for breast cancer. J National Cancer Inst 1993;85:1644-56.

  3. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and the risk of breast cancer. Results from epidemiologic studies. Am J Obstet Gynecol 1999;168:1473-80.

  4. Collaborative Group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives. Lancet 1996;347:1713-27.

  5. Colditz GA. Postmenopausal estrogens and breast cancer. J Soc Gynecol Invest 1996;2:50-6.

  6. Colditz GA, Willet WC, Hunter DJ, Stampfer MJ, Manson JE, Henneken CH, Rosner BA, Speizer FE. Family history, age and risk of breast cancer. Prospective data from the Nurses’ Health Study. JAMA 1993;270:338-43.

  7. The Women’s Health Initiative study group. Design of the women’s health. Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.

  8. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Consensus Statement. J Clin Endocrinol Metab 1998;83:1993-99.

  9. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.

  10. O’Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-61.

  11. Gajdos C, Tartter PI, Babinszki A. Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 2000,95:513-8.

  12. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59.

  13. Beckman MW, Jap D, Djahamsouzi S, Nestle-Krämling C, Kuschel B, Dall P, Brumm C, Bender HG. Hormone replacement therapy after treatment of breast cancer: Effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001;60:199-206.




2020     |     www.medigraphic.com